Ann: Appendix 4C - quarterly, page-6

I still think the acquisition is a good one given it diversifies the range of medical devices the company can offer. While no revenue growth isn't good, keep in mind all revenue so far comes from the 1A device, and the company has outlaid significant capital in acquiring the BP+ and now the Thor products. Revenue will certainly grow over the coming quarters as these products begin selling under the UCM banner.

But yes, it would have been nice to see some organic growth of the core device as well. I'm still 50/50 on the SPP, it may come down to what the SP is at the closing date.